Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours
NCT02591030Phase 3Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Dec 2015
- Primary completion
- Jun 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of mFOLFIRINOX in cholangiocarcinoma (CCA) (2 arms), sponsored by CHU Saint-Etienne. Primary endpoints: Progression-Free Survival at 6 months and Overall Survival at 6 years. Started Dec 2015; status: completed.
02
Drugs
mFOLFIRINOX
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02591030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02591030.